Phase I/II Huntington’s Data From uniQure Draw Caution On Biomarker
Clinical, Functional Data Show Improvements
The biotech company released updated data on AMT-130 meeting functional and clinical endpoints but missing one biomarker, raising questions about durability. But uniQure downplayed concerns.
